Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Aaron M. Caola"'
Publikováno v:
The American naturalist. 191(1)
Color polymorphisms have long been of evolutionary interest for their diverse roles, including mate choice, predator avoidance, and pollinator attraction. While color variation is often under strong selection, some taxa demonstrate unexpectedly high
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d2eaf3666907546f555396e3555e3047
https://pubmed.ncbi.nlm.nih.gov/29244558
https://pubmed.ncbi.nlm.nih.gov/29244558
Autor:
David Liu, Marzia Capelletti, Aldo M. Roccaro, Adriana Perilla Glen, Patrick Henrick, Gad Getz, Claudia Freymond, Karma Salem, Antonio Sacco, Daisy Huynh, Aaron M. Caola, Nikhil C. Munshi, Jihye Park, Irene M. Ghobrial, Eliezer M. Van Allen, Salomon Manier
Publikováno v:
Blood. 128:237-237
Introduction: Recent data shows that multiple myeloma (MM) almost always arises from precursor states called Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM), but not all patients with MGUS or SMM develo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f29b1847c376f853965431c7d485216
https://doi.org/10.1182/blood.v128.22.237.237
https://doi.org/10.1182/blood.v128.22.237.237
Autor:
Kenneth C. Anderson, Bradley Rivotto, Paul G. Richardson, Patrick Henrick, Alexandra Savell, Irene M. Ghobrial, Ashraf Badros, Rodrigo O. Maegawa, Jacalyn Rosenblatt, Saad Z. Usmani, Andrew Yee, James J. Vredenburgh, Claudia E. Paba-Prada, Jeffrey Matous, Charles M. Farber, Joseph Cappuccio, Kaitlen Reyes, Aaron M. Caola, Jeffrey S. Wisch, Robert L. Schlossman, Jacob P. Laubach, Kimberly Noonan, Nikhil C. Munshi
Publikováno v:
Blood. 128:976-976
Background This study aimed to determine the benefit of early therapeutic intervention with the combination of elotuzumab, Lenalidomide, and Dexamethasone in patients with high-risk smoldering multiple myeloma (SMM). ClinicalTrials.gov Identifier: NC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ca28bd359a20761a9ca76d9fbc5eb18
https://doi.org/10.1182/blood.v128.22.976.976
https://doi.org/10.1182/blood.v128.22.976.976
Autor:
Jacalyn Rosenblatt, Stew Kroll, Ira Zackon, Philippe Armand, Emily Lai, Kenneth H. Shain, Kaitlen Reyes, Bradley Rivotto, Aaron M. Caola, Jacob P. Laubach, Joseph Cappuccio, Craig W. Reynolds, Alexandra Savell, Kenneth C. Anderson, Damian Handisides, Irene M. Ghobrial, Michael Gary Martin, Tillman E. Pearce, Paul G. Richardson, Laura Stampleman, Andrew Yee, Patrick Henrick, Noopur Raje, Robert L. Schlossman
Publikováno v:
Blood. 128:2122-2122
Purpose: This phase 1/2 study was conducted to determine the maximum tolerated dose (MTD), safety, tolerability, and clinical activity of the hypoxia-activated prodrug evofosfamide (TH-302) and dexamethasone with or without bortezomib in relapsed/ref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb7d3d5b463a74fad50a87b098f3f7bf
https://doi.org/10.1182/blood.v128.22.2122.2122
https://doi.org/10.1182/blood.v128.22.2122.2122
Autor:
Irene M. Ghobrial, Jeffrey Matous, Jorge J. Castillo, Patrick Henrick, Joseph Cappuccio, Steven P. Treon, Emily Lai, Aaron M. Caola
Publikováno v:
Journal of Clinical Oncology. 34:8065-8065
8065Background: This follow-up study aimed to update the progression-free survival (PFS) and identify responder subgroups in the phase II trial of Bortezomib and Rituximab in patients with Waldenst...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f765b00f0e506902be78c529c2b673f
https://doi.org/10.1200/jco.2016.34.15_suppl.8065
https://doi.org/10.1200/jco.2016.34.15_suppl.8065
Autor:
Robert L. Schlossman, Nikhil C. Munshi, Kenneth H. Shain, Kimberly Noonan, Irene M. Ghobrial, Alexandra Savell, Ranjit Banwait, Frank G. Basile, Jacob P. Laubach, Abdel Kareem Azab, Aaron M. Caola, Claudia E. Paba-Prada, Paul G. Richardson, Pamela Crilley, Caroline Block, Emily Lai, Michael Constantine, Stacey Chuma, Patrick Henrick, Kenneth C. Anderson, Joseph Cappuccio, James Vredenburg
Publikováno v:
Blood. 126:4256-4256
PURPOSE: This study aimed to determine activity and safety of the CXCR4 inhibitor plerixafor in combination with bortezomib and dexamethasone in patients with relapsed or refractory Multiple Myeloma (MM). This was based on our preclinical studies sho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77fa17b39dbd8db7761cf6b6ebf4f7ab
https://doi.org/10.1182/blood.v126.23.4256.4256
https://doi.org/10.1182/blood.v126.23.4256.4256